Our strength is in the prediction of FDA-approved endpoints through in silico clinical trial simulations of both acute and chronic inflammatory diseases. The speed and efficiency of our proprietary software platform represents eight years of work by our team of experts. We deliver proprietary mathematical models encompassing biological pathways and interactions that span levels of detail from intracellular signaling pathways, cellular interactions, and organ systems up to the whole organism. Our models can also incorporate the continuum of effects of individual variability within trial populations.
